Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Cervical CancersHPV TestingNanopore SequencingHPV Integration Site DetectionRapid Diagnosis
Interventions
DIAGNOSTIC_TEST

HPV integration

Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06644677 - Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis | Biotech Hunter | Biotech Hunter